Candidiasis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Candidiasis – Pipeline Review, H1 2017’, provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Candidiasis

– The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects

– The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Candidiasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amplyx Pharmaceuticals Inc

Bakker Medical Srl

Biomar Microbial Technologies

Biosergen AS

Cidara Therapeutics Inc

CSA Biotechnologies LLC

Daewoong Pharmaceutical Co Ltd

Dermala Inc

General Biologicals Corp

Grupo Ferrer Internacional SA

Hsiri Therapeutics LLC

iCo Therapeutics Inc.

ImmunoClin Corp

Matinas BioPharma Holdings Inc

Nanomerics Ltd

NovaDigm Therapeutics Inc

Novartis AG

Onxeo SA

Scynexis Inc

Sealife PHARMA GMBH

Viamet Pharmaceuticals Inc

Visterra Inc

Wellstat Vaccines LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Candidiasis - Overview 8

Candidiasis - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Candidiasis - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Candidiasis - Companies Involved in Therapeutics Development 27

Amplyx Pharmaceuticals Inc 27

Bakker Medical Srl 27

Biomar Microbial Technologies 28

Biosergen AS 28

Cidara Therapeutics Inc 29

CSA Biotechnologies LLC 29

Daewoong Pharmaceutical Co Ltd 30

Dermala Inc 30

General Biologicals Corp 31

Grupo Ferrer Internacional SA 31

Hsiri Therapeutics LLC 32

iCo Therapeutics Inc. 32

ImmunoClin Corp 33

Matinas BioPharma Holdings Inc 33

Nanomerics Ltd 34

NovaDigm Therapeutics Inc 34

Novartis AG 35

Onxeo SA 35

Scynexis Inc 36

Sealife PHARMA GMBH 36

Viamet Pharmaceuticals Inc 37

Visterra Inc 37

Wellstat Vaccines LLC 38

Candidiasis - Drug Profiles 39

(clotrimazole + diclofenac sodium) - Drug Profile 39

61894700 - Drug Profile 40

AC-17 - Drug Profile 41

amphotericin B - Drug Profile 42

amphotericin B - Drug Profile 44

amphotericin B - Drug Profile 48

Amphotericin B sodium - Drug Profile 49

Antibody to Target Ece1 for Candidiasis - Drug Profile 51

APX-001 - Drug Profile 52

APX-001A - Drug Profile 54

arasertaconazole - Drug Profile 55

B-4010 - Drug Profile 56

BL-5923 - Drug Profile 57

BSG-005 - Drug Profile 58

candidiasis vaccine - Drug Profile 59

CD-101 - Drug Profile 60

Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 64

CSA-13 - Drug Profile 65

Drug for Candidiasis - Drug Profile 67

DWP-06081 - Drug Profile 68

Forazoline A - Drug Profile 69

iCo-010 - Drug Profile 70

interleukin-22 - Drug Profile 71

JSM-11 - Drug Profile 72

KSL-W - Drug Profile 73

miconazole nitrate - Drug Profile 74

Monoclonal Antibodies for Candidiasis - Drug Profile 76

Monoclonal Antibody for Candidiasis - Drug Profile 77

Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile 78

mutanobactin A - Drug Profile 79

NDV-3 - Drug Profile 80

NDV-3A - Drug Profile 82

NP-339 - Drug Profile 84

obliquumol - Drug Profile 85

Occidiofungin - Drug Profile 86

P-113Du - Drug Profile 87

P-113Tri - Drug Profile 88

PAC-113 - Drug Profile 89

Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile 91

Prof-002 - Drug Profile 92

Recombinant Enzyme for Candidiasis - Drug Profile 93

Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile 94

SCY-078 - Drug Profile 95

SLP-0901 - Drug Profile 100

SLP-0904 - Drug Profile 101

Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 102

Small Molecule for Fungal Infections - Drug Profile 103

Small Molecules for Aspergillosis and Candidiasis - Drug Profile 104

Small Molecules for Candidiasis - Drug Profile 105

Small Molecules for Candidiasis - Drug Profile 106

Small Molecules for Candidiasis - Drug Profile 107

Small Molecules for Fungal Infections - Drug Profile 108

Small Molecules for Fungal Infections - Drug Profile 109

Small Molecules for Systemic Candidiasis - Drug Profile 110

Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile 111

Synthetic Peptides for Candidiasis - Drug Profile 112

Synthetic Peptides for Infections Diseases and Oncology - Drug Profile 113

TOL-463 - Drug Profile 114

Vaccine to Target Ece1 for Candidiasis - Drug Profile 115

Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile 116

VIS-FNG - Drug Profile 117

VT-1129 - Drug Profile 118

VT-1161 - Drug Profile 120

Candidiasis - Dormant Projects 126

Candidiasis - Discontinued Products 129

Candidiasis - Product Development Milestones 130

Featured News & Press Releases 130

Appendix 141

Methodology 141

Coverage 141

Secondary Research 141

Primary Research 141

Expert Panel Validation 141

Contact Us 141

Disclaimer 142

List of Tables

List of Tables

Number of Products under Development for Candidiasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Candidiasis – Pipeline by Amplyx Pharmaceuticals Inc, H1 2017

Candidiasis – Pipeline by Bakker Medical Srl, H1 2017

Candidiasis – Pipeline by Biomar Microbial Technologies, H1 2017

Candidiasis – Pipeline by Biosergen AS, H1 2017

Candidiasis – Pipeline by Cidara Therapeutics Inc, H1 2017

Candidiasis – Pipeline by CSA Biotechnologies LLC, H1 2017

Candidiasis – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Candidiasis – Pipeline by Dermala Inc, H1 2017

Candidiasis – Pipeline by General Biologicals Corp, H1 2017

Candidiasis – Pipeline by Grupo Ferrer Internacional SA, H1 2017

Candidiasis – Pipeline by Hsiri Therapeutics LLC, H1 2017

Candidiasis – Pipeline by iCo Therapeutics Inc., H1 2017

Candidiasis – Pipeline by ImmunoClin Corp, H1 2017

Candidiasis – Pipeline by Matinas BioPharma Holdings Inc, H1 2017

Candidiasis – Pipeline by Nanomerics Ltd, H1 2017

Candidiasis – Pipeline by NovaDigm Therapeutics Inc, H1 2017

Candidiasis – Pipeline by Novartis AG, H1 2017

Candidiasis – Pipeline by Onxeo SA, H1 2017

Candidiasis – Pipeline by Scynexis Inc, H1 2017

Candidiasis – Pipeline by Sealife PHARMA GMBH, H1 2017

Candidiasis – Pipeline by Viamet Pharmaceuticals Inc, H1 2017

Candidiasis – Pipeline by Visterra Inc, H1 2017

Candidiasis – Pipeline by Wellstat Vaccines LLC, H1 2017

Candidiasis – Dormant Projects, H1 2017

Candidiasis – Dormant Projects, H1 2017 (Contd..1), H1 2017

Candidiasis – Dormant Projects, H1 2017 (Contd..2), H1 2017

Candidiasis – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Candidiasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports